REG - Shield Therapeutics - Q2 2025 Trading Update

Shield TherapeuticsAnnouncement

23/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250723:nRSW2109Sa&default-theme=true

RNS Number : 2109S  Shield Therapeutics PLC  23 July 2025

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by
virtue of the European Union (Withdrawal) Act 2018). Upon the publication of
this announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Q2 2025 Trading Update

Q2 2025 ACCRUFeR® net revenues doubled over Q1 2025 to $12.8m,

47,000 prescriptions, and an average net selling price of $231

Cash and cash equivalents remain robust at $10.8m at period end

Guidance remains on track to turn cash flow positive by the end of 2025

 

London, UK, 23 July 2025: Shield Therapeutics plc (LSE: STX), a
commercial-stage pharmaceutical company specialising in iron deficiency,
provides an unaudited Q2 2025 trading update.

 

In the second quarter of 2025, Shield reported unaudited ACCRUFeR® net
revenues of $12.8m, doubling Q1 2025 net revenues of $6.4m. ACCRUFeR® total
prescriptions grew strongly to c. 47,000 prescriptions with an average net
selling price of $231 compared to c. 36,800 and $187 respectively in Q1 2025.
The Company remains on track to achieve its prior guidance of turning cash
flow positive by the end of 2025.

Q2 2025 Key Business Metrics:

·    ACCRUFeR® net revenue of $12.8m (Q1 2025: $6.4m and Q2 2024: $6.9m).

·    ACCRUFeR® average net selling price of $231 (Q1 2025: $187 and Q2
2024: $171).

·    ACCRUFeR® prescriptions of c. 47,000, with c. 23% consignment-based
prescriptions that were dispensed at a significantly subsidised price to
patients and were not yet reimbursed by payors.

·    Cash and cash equivalents of $10.8m as of 30 June 2025 ($10.5m as of
31 March 2025). The increase in cash balance compared to Q1 2025 was primarily
driven by the milestone payments received from VITAL-NET, Inc. of $665k
supporting the exclusive licensing agreement in Japan for ACCRUFeR®, and from
Norgine BV in Europe of €0.5m supporting the pediatric filing process with
the EMA.

Anders Lundstrom, Chief Executive Officer, commented: "I am excited to see the
robust performance for ACCRUFeR® in Q2 2025 which followed on from a strong
end to Q1 2025.  This positions us well as we build momentum behind
ACCRUFeR® going into the 2nd half of the year and beyond. Shield and our
partner, Viatris, are pleased with the continued adoption of ACCRUFeR® in the
market, which reinforces our belief that the market potential of ACCRUFeR® is
significant.  We are committed to delivering further growth and making
ACCRUFeR® the oral iron of choice for patients with iron deficiency, with or
without anemia. Finally, cash balances increased slightly during the quarter,
and these results maintain our clear trajectory toward reaching cash flow
positivity by the close of 2025."

 

Investor Presentation via Investor Meet Company

 

CEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live
online presentation relating to the Q2 2025 update via the Investor Meet
Company platform at 3:00 pm (BST) on 23 July 2025.

 

The presentation is open to all existing and potential investors. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
2.00 pm (BST) or at any time during the live presentation. Investors can sign
up to Investor Meet Company for free and add to meet Shield Therapeutics plc
via:

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
(https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor)

 

Investors who already follow Shield Therapeutics plc on the Investor Meet
Company platform will automatically be invited.

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Anders Lundstrom, CEO                                                                          +44 (0) 191 511 8500
 Santosh Shanbhag, CFO                                                                          investorrelations@shieldtx.com (mailto:investorrelations@shieldtx.com)

 Stephanie Hicks, Investor Relations

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel                                                                                    +44 (0)20 7418 8900

 Joint Broker                                                                                   +44 (0)20 7220 0500
 Cavendish Ltd
 Geoff Nash / Isaac Hooper / Nigel Birks / Harriet
 Ward

 

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients.

 

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company launched
ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration agreement
with Viatris Inc. Outside of the U.S., the Company licensed the rights to five
specialty pharmaceutical companies. FeRACCRU® is commercialized in the UK and
European Union by Norgine B.V., which also has marketing rights in Australia
and New Zealand. Shield also has an exclusive license agreement with Beijing
Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization
of ACCRUFeR®/ FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea
Pharma Co., Ltd. for the Republic of Korea, KYE Pharmaceuticals Inc. for
Canada and with VITAL-NET, Inc. For Japan.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

 

Forward-Looking Statements:

This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of historical
fact should be considered forward-looking statements.  These forward-looking
statements are based on management's current expectations and include
statements related to the commercial strategy for ACCRUFeR®/FeRACCRU®. These
statements are neither promises nor guarantees, but involve known and unknown
risks and uncertainties, many of which are beyond our control, that may cause
actual results and performance or achievements to be materially different from
management's expectations expressed or implied by the forward-looking
statements, including, but not limited to, risks associated with the Company's
business and results of operations, competition, and other market factors.
The forward-looking statements made in this press release represent
management's expectations as of the date of this press release, and except as
required by law, the Company disclaims any obligation to update any
forward-looking statements contained in this release, even if subsequent
events cause its views to change.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTUOVVRVBUBURR